| | 706779-91-1 Basic information More.. |
| Product Name: | Pimavanserin | | Synonyms: | Pimavanserin;PIMAVANSERIN/1-(4-FLUOROBENZYL)-3-(4-ISOBUTOXYBENZYL)-1-(1-METHYLPIPERIDIN-4-YL)UREA;Unii-jz963p0dik;Pimavamserin;1-[(4-fluorophenyl)Methyl]-1-(1-Methylpiperidin-4-yl)-3-{[4-(2-Methylpropoxy)phenyl]Methyl}urea;N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-yl)-N'-[[4-(2-Methylpropyloxy)phenyl]Methyl]carbaMide;N-[(4-Fluorophenyl)Methyl]-N-(1-Methyl-4-piperidinyl)-N'-[[4-(2-Methylpropoxy)phenyl]Methyl]urea;Urea,N-[(4-fluorophenyl)Methyl]-N-(1-Methyl-4-piperidinyl)-N'-[[4-(2-Methylpropoxy)phenyl]Methyl]- | | CAS: | 706779-91-1 | | MF: | C25H34FN3O2 | | MW: | 427.55 | | EINECS: | 1806241-263-5 | | Mol File: | 706779-91-1.mol |  |
Use
Pimavanserin is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis and is also being researched for the treatment of Alzheimer’s disease psychosis, schizophrenia, agitation, and major depressive disorder. Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist.
Pimavanserin acts as an inverse agonist and antagonist at serotonin 5-HT2A [5] receptors with high binding affinity (Ki 0.087 nM) and at serotonin 5-HT2C receptors with lower binding affinity (Ki 0.44 nM). Pimavanserin shows low binding to σ1 receptors (Ki 120 nM) and has no appreciable affinity (Ki >300 nM) to serotonin 5-HT2B, dopamine (including D2), muscarinic acetylcholine, histamine, or adrenergic receptors, or to calcium channels.
- Pimavanserin
-
- US $650.00-350.00 / Kg/Bag
- 2025-05-15
- CAS:706779-91-1
- Min. Order: 1Kg/Bag
- Purity: 99% up, High Density
- Supply Ability: 20 tons
- Pimavanserin
-
- US $0.00-0.00 / kg
- 2025-05-15
- CAS:706779-91-1
- Min. Order: 1kg
- Purity: 98
- Supply Ability: 1000
- Pimavanserin
-
- US $44.00-108.00 / mg
- 2025-04-27
- CAS:706779-91-1
- Min. Order:
- Purity: 99.69%
- Supply Ability: 10g
|
|
706779-91-1
Recommend Suppliers |
|